Dr. Alison Schram, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Area of expertise
Ovarian Cancer
Alison Schram, MD has run 7 trials for Ovarian Cancer. Some of their research focus areas include:
Solid Tumors
Alison Schram, MD has run 6 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Monmouth
Clinical Trials Alison Schram, MD is currently running
PC14586
for Solid Tumors
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Recruiting
1 award
Phase 1 & 2
5 criteria
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting
1 award
Phase 2
More about Alison Schram, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Alison Schram, MD has experience with
- Selumetinib Sulfate
- Olaparib
- Zenocutuzumab (MCLA-128)
- RMC-5552
- ELU001
- PC14586
Breakdown of trials Alison Schram, MD has run
Ovarian Cancer
Solid Tumors
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alison Schram, MD specialize in?
Alison Schram, MD focuses on Ovarian Cancer and Solid Tumors. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are NRG1 positive.
Is Alison Schram, MD currently recruiting for clinical trials?
Yes, Alison Schram, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alison Schram, MD has studied deeply?
Yes, Alison Schram, MD has studied treatments such as Selumetinib Sulfate, Olaparib, Zenocutuzumab (MCLA-128).
What is the best way to schedule an appointment with Alison Schram, MD?
Apply for one of the trials that Alison Schram, MD is conducting.
What is the office address of Alison Schram, MD?
The office of Alison Schram, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10021 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.